Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity

Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lake, Jordan E., McComsey, Grace A., Hulgan, Todd, Wanke, Christine A., Mangili, Alexandra, Walmsley, Sharon L., Currier, Judith S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567084/
https://www.ncbi.nlm.nih.gov/pubmed/26380350
http://dx.doi.org/10.1093/ofid/ofv059
_version_ 1782389772443975680
author Lake, Jordan E.
McComsey, Grace A.
Hulgan, Todd
Wanke, Christine A.
Mangili, Alexandra
Walmsley, Sharon L.
Currier, Judith S.
author_facet Lake, Jordan E.
McComsey, Grace A.
Hulgan, Todd
Wanke, Christine A.
Mangili, Alexandra
Walmsley, Sharon L.
Currier, Judith S.
author_sort Lake, Jordan E.
collection PubMed
description Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 weeks of raltegravir was associated with a 6.4% VAT decline. Raltegravir for 24 weeks was associated with improvements in lipids.
format Online
Article
Text
id pubmed-4567084
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-45670842015-09-14 Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity Lake, Jordan E. McComsey, Grace A. Hulgan, Todd Wanke, Christine A. Mangili, Alexandra Walmsley, Sharon L. Currier, Judith S. Open Forum Infect Dis Brief Reports Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 weeks of raltegravir was associated with a 6.4% VAT decline. Raltegravir for 24 weeks was associated with improvements in lipids. Oxford University Press 2015-04-26 /pmc/articles/PMC4567084/ /pubmed/26380350 http://dx.doi.org/10.1093/ofid/ofv059 Text en © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Brief Reports
Lake, Jordan E.
McComsey, Grace A.
Hulgan, Todd
Wanke, Christine A.
Mangili, Alexandra
Walmsley, Sharon L.
Currier, Judith S.
Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
title Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
title_full Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
title_fullStr Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
title_full_unstemmed Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
title_short Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
title_sort switch to raltegravir from protease inhibitor or nonnucleoside reverse-transcriptase inhibitor does not reduce visceral fat in human immunodeficiency virus-infected women with central adiposity
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567084/
https://www.ncbi.nlm.nih.gov/pubmed/26380350
http://dx.doi.org/10.1093/ofid/ofv059
work_keys_str_mv AT lakejordane switchtoraltegravirfromproteaseinhibitorornonnucleosidereversetranscriptaseinhibitordoesnotreducevisceralfatinhumanimmunodeficiencyvirusinfectedwomenwithcentraladiposity
AT mccomseygracea switchtoraltegravirfromproteaseinhibitorornonnucleosidereversetranscriptaseinhibitordoesnotreducevisceralfatinhumanimmunodeficiencyvirusinfectedwomenwithcentraladiposity
AT hulgantodd switchtoraltegravirfromproteaseinhibitorornonnucleosidereversetranscriptaseinhibitordoesnotreducevisceralfatinhumanimmunodeficiencyvirusinfectedwomenwithcentraladiposity
AT wankechristinea switchtoraltegravirfromproteaseinhibitorornonnucleosidereversetranscriptaseinhibitordoesnotreducevisceralfatinhumanimmunodeficiencyvirusinfectedwomenwithcentraladiposity
AT mangilialexandra switchtoraltegravirfromproteaseinhibitorornonnucleosidereversetranscriptaseinhibitordoesnotreducevisceralfatinhumanimmunodeficiencyvirusinfectedwomenwithcentraladiposity
AT walmsleysharonl switchtoraltegravirfromproteaseinhibitorornonnucleosidereversetranscriptaseinhibitordoesnotreducevisceralfatinhumanimmunodeficiencyvirusinfectedwomenwithcentraladiposity
AT currierjudiths switchtoraltegravirfromproteaseinhibitorornonnucleosidereversetranscriptaseinhibitordoesnotreducevisceralfatinhumanimmunodeficiencyvirusinfectedwomenwithcentraladiposity

Ejemplares similares